Supplementary Information

Optimal Design of Thiostrepton-derived Thiopeptide Antibiotics and Their Potential Application against Oral Pathogens

Jian Wang^{#,a}, Zhi Lin^{#,b,c}, Xuebing Bai^a, Jiang Tao^{*,a} and Wen Liu^{*,b,d}

^a Department of General Dentistry, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, 639 Zhizaoju Road, Shanghai 200011, China. ^b State Key Laboratory of Bioorganic and Natural Products Chemistry, Center for Excellence on Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China. ^c State Key Laboratory of Microbial Metabolism, School of Life Science & Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China. ^d Huzhou Center of Bio-Synthetic Innovation, 1366 Hongfeng Road, Huzhou 313000, China.

[#]These Authors equally contributed to this work.

* To whom correspondence should be addressed: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Rd., Shanghai 200032, China. Wen Liu, Email: <u>wliu@mail.sioc.ac.cn</u>, Tel: 86-21-54925111, Fax: 86-21-64166128.

Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Rd., Shanghai 200011, China. Jiang Tao, Email: <u>taojiang_doctor@hotmail.com</u>, Tel: 86-21-23271699-5202.

1. Supplementary Methods

- 1.1. General materials and methods
- 1.2. Mutant construction
- 1.3. Chemical purification and characterization
- 1.4. Physical property and bioactivity of TSR and its analogs

2. Supplementary Results

- Fig. S1. Structures of TSR, 5'-fluoro-TSR, 6'-fluoro-TSR and 12'-methyl-TSR
- Fig. S2. The UV spectra of 5'-fluoro-SIO
- Fig. S3. DNA examination.
- Fig. S4. Structure of 5'-fluoro-SIO
- Fig. S5. NMR spectra of 5'-fluoro-SIO
- Table S1. Strains and plasmids used in this study
- Table S2. Primers used in this study
- Table S3. ¹H and ¹³C NMR spectroscopic data for 5'-fluoro-SIO
- Table S4. MALDI High Resolution MS data of 5'-fluoro-SIO

3. Supplementary References

1. Supplementary Methods

1.1. General materials and methods

Materials, Bacterial strains, and Plasmids. Biochemicals and media were purchased from Sinopharm Chemical Reagent Co., Ltd. (China), Oxoid Ltd. (U.K.) or Sigma-Aldrich Co. LLC. (USA) unless otherwise stated. Enzymes were purchased from Takara Biotechnology Co. Ltd. (China). Restriction endonucleases were purchased from Thermo Fisher Scientific Co. Ltd. (USA). Chemical reagents were purchased from standard commercial sources. The bacterial strains and plasmids used in this study are listed in Table S1.

DNA Isolation, Manipulation, and Sequencing. DNA isolation and manipulation in *E. coli* or *streptomyces* were carried out according to standard methods¹. PCR amplifications were carried out on an Applied Biosystems Veriti Thermal Cycler using either Taq DNA polymerase (Vazyme Biotech Co. Ltd, China) for routine genotype verification or Kod DNA polymerase (Takara Biotechnology Co., Ltd.) or PrimeSTAR HS DNA polymerase (Takara Biotechnology Co., Ltd.) applification. Primer synthesis was performed at Shanghai Sangon Biotech Co. Ltd. (China). DNA sequencing was performed at Shanghai Majorbio Biotech Co. Ltd. (China). Primers used for diagnostic PCR were listed in Table S2.

Sequence Analysis. TSR biosynthetic gene clusters (BGCs) were obtained from NCBI database(https://www.ncbi.nlm.nih.gov/nuccore/FJ436358.1). DNA hairpin was determined by using the programs from Vector NTI Advance 11. 0 software (Invitrogen).

General Chemical Analysis. High performance liquid chromatography (HPLC) analysis was carried out on an Agilent 1260 HPLC system (Agilent Technologies Inc., USA) equipped with a DAD detector. Semi-preparative HPLC was performed on an Agilent 1100 system. HPLC Electrospray ionization MS (HPLC-ESI-MS) and tandem MS (MS/MS) were performed on a Thermo Fisher LTQ Fleet ESI-MS spectrometer (Thermo Fisher Scientific Inc., USA), and the data were analyzed using Thermo Xcalibur software. ESI-high resolution MS (ESI-HR-MS) analysis was carried out on an instrument consisting of a 1260 HPLC system or a 6538 UHD quadrupole time of flight (QTOF) high resolution mass spectrometry (Agilent Technologies, Santa Clara, USA).

NMR data were recorded on a Bruker AV-600 or Bruker AV-500 spectrometer (Bruker Co. Ltd, Germany).

1.2. Mutant construction

Gene Inactivation of tsrT. Genomic DNA of SL2051 strain served as the template for PCR amplification unless otherwise stated. To exclude polar effects on downstream gene expression, gene inactivation in SL2051 was performed by in-frame deletion. The gene tsrT was inactivated using a modified CRISPR-Editing method.² Briefly, the 20-bp sg sequence was generated and cloned into the plasmid pWHU2653 through homologous recombination among the two 140-bp PCR products amplified from pWHU2653 using the primer pairs sg-for/tsrT-sg-rev and tsrT-sgfor/sg-rev, respectively (Table S3), and Nhel/Xbal-digested pWHU2653, yielding pWHU1001. 2kb PCR products amplified from the genome of SL2051 using the primer pairs tsrT-L-for/tsrT-Lrev and *tsrT*-R-for/*tsrT*-R-rev were obtained as the left and right arms of gene *tsrT* (Table S3). HindIII-digested pWHU1001, left arm and right arm of gene tsrT were recombined to generate pWHU1002. To transfer pWHU1002 into the template SL2051, conjugation between E. coli ET 12567 (pUZ8002) and SL2051 was carried out. The colonies that growing at 5-flucytodine-resistant at 30°C were identified as integrating mutants, in which a single-crossover homologous recombination event took place. Then the resulting apramycin-sensitive isolates were subjected to PCR amplification to examine the genotype of the SL3051 mutant strain (Figure S3). PCR amplification for examination primers were tsrT-Y-for/ tsrT-Y-rev (Table S3). Previous constructed pSL3051 containing the gene that encodes TsrH-Ile1Val-Ala2Ser was then introduced into SL3051 by conjunction to acquire the targeted strain SL3052.

1.3. Chemical purification and characterization

Fermentation, Examination and Isolation of 5'-fluoro-SIO. Cultivation, production and analysis of thiostrepton variants were performed according to the methods described previously.^{3,4,8} The methanol sample was subjected to HPLC and HPLC-MS analysis on an Agilent Zorbax column (SB-C18, 4.6×250 mm, 5µm, Agilent Technologies Inc., USA) by gradient elution of solvent A (H₂O + 0.1% formic acid) and solvent B (acetonitrile + 0.1% formic acid) with a flow rate of 1 mL / min over a 50 min period as follows: T = 0 min, 5% B; T = 20 min, 15% B; T = 30 min, 40% B;

T = 37 min, 55% B; T = 40 min, 85% B; T = 47 min, 85% B; T = 50 min, 5% B. Absorbance was monitored at 254 nm. Related data were analyzed using Thermo Xcalibur software. Isolation and purification of the thiostrepton variants were performed according to the methods described previously⁵.

1.4. Physical property and bioactivity of TSR and its analogs

Minimum Inhibitory Concentrations (MICs). Oral Gram-positive facultative anaerobes (Streptococcus mutans UA159, Lactobacillus acidophilus ATCC 4356 and Actinomyces viscosus ATCC 19246) and Gram-negative obligate anaerobes (Fusobacterium nucleatum ATCC 25286 and Porphyromonas gingivalis ATCC 33277) were used to determine antibacterial activities in vitro. Brain-heart infusion broth (BHI; Difco Laboratories, Detroit, MI, USA) was used for culture of facultative anaerobic bacteria and incubated for 24 h at 37 °C. For the obligate anaerobic bacteria, F. nucleatum and P. gingivalis, BHI containing hemin (Sigma-Aldrich, St. Louis, MO, USA) and menadione(Sigma-Aldrich, St. Louis, MO, USA) (BHI-modified) was used and incubated for 48 h at 37 °C. The procedure was in accordance to standard procedure recommended by the Clinical Laboratory Standard Institute (CLSI) with a few modifications^{6,7}. The broth microdilution technique was operated to determine the MIC values of the tested compounds as previously stated^{4,5}. Each tested sample was dissolved in DMSO to produce stock solution (100 μ g/ml), which was serially diluted into 100 μ L of BHI or BHI-modified broth according to the corresponding strain in a 96well Microtiter plate to a final concentration ranging from 10 to 0 µg/ml in two-fold serial. 100 µL of the testing strain (calculated according to 0.5 McFarland diluted 1:100 to a final concentration of $0.5-1*10^6$ CFU/ml) was then added into each well of the microtiter plate, followed by 24–48 h of incubation period either in aerobic or anaerobic condition accordingly (S. mutans, L. acidophils and A. viscosus for 24 h, F. nucleatum and P. gingivalis for 48 h. Sodium fluoride (NaF) and chlorhexidine (CHX) were chosen as Gram-positive controls, Levofloxacin (LVX) and tinidazole (TNZ) were chosen as Gram-negative controls, respectively. The MIC was defined as the lowest concentration that inhibited visible bacterial growth. All tests were carried out in 3 times.

Water solubility. The solubility was measured according to a saturation shake-flask method described previously^{4,5}. To determine the solubility of TSR, SIO, 5'-fluoro-TSR and 5'-fluoro-SIO, an excess amount of solid was added into 1 mL of water in a vial. The vial was gently stirred over a 24-hour period at the room temperature to ensure the equilibrium of the solution. A 0.22 µm centrifugal filter unit (Millipore Utrafree-MC, USA) was used for filtration to remove the excess solid. The saturated solution was then subjected to HPLC analysis to determine the concentration of the sample based on the established calibration curve. To establish the calibration curve, a set of the solutions for TSR, SIO, 5'-fluoro-TSR and 5'-fluoro-SIO varying in concentration were analyzed independently by HPLC. The peak areas correlated with the concentrations were fitted to a regression equation, resulting in a linear standard curve for estimating the concentration.





Fig. S2. The UV spectra of 5'-fluoro-SIO (254 nm)



Fig. S3. DNA examination. DNA examination by agarose gel electrophoresis analysis. The gel contains the DNA ladder (left) and the PCR products of mutant SL3051 (665 bp) and SL2051 (2340 bp) (right)



Fig. S4. Structure of 5'-fluoro-SIO



Fig. S5. NMR spectra of 5'-fluoro-SIO. **A**. ¹H spectrum. **B**. ¹³C spectrum. **C**. COSY spectrum. **D**. HSQC spectrum. **E**. HMBC spectrum. **F**. ¹⁹F NMR. (CDCl₃:CD₃OD=4:1)



A. 1 H NMR







10

-10

-20 -30 -50 -60 -70

-80

-90 -100 f1 (ppm)

-40



-120 -130 -140 -150 -160

-110

-190

-200

-170

-180

2. Supplementary Tables

Table S1. Strains and plasmids used in this study

Strains/Plasmids	Description	Source / Reference	
Strains			
Escherichia coli			
DH5a	Host for general cloning	Transgen	
ET12567	Donor strain for conjugation between	1	
(pUZ8002)	E.coli and Streptomyces	1	
Streptococcus	Oral caries pathogenic bacteria,	ATCC	
mutans UA159	Gram-positive		
Lactobacillus	Oral caries pathogenic bacteria		
acidophilus ATCC	Gram-nositive	ATCC	
4356	Gram positive		
Actinomyces	Oral caries pathogenic bacteria.	ATCC	
viscosus ATCC	Gram-positive		
19246			
Fusobacterium	Oral periodontopathic bacteria.		
nucleatum ATCC	Gram-negative	ATCC	
25286			
Porphyromonas	Oral periodontonathic hacteria		
gingivalis ATCC	Gram-negative	ATCC	
33277	Gram-negative		
Streptomyces			
laurentii	Wild type strain, thiostrepton(TSR)-	ATCC	
laurentii	producing strain		
	S. laurentii derivative, in which the		
SL2051	codon GAG for Glu-7 of TsrH was	4	
	mutated into the stop codon TAG		
SI 3051	The <i>tsrT</i> in-frame deletion mutant of	This study	
525051	SL2051		
SL3052	SL3051 derivative, containing pSL-	This study	
515052	I1V-A2S		
Plasmids			
pWHU2653	E. coli-Streptomyces shuttle vector	2	
	for gene inactivation	2	
pSET152	E. coli-Streptomyces shuttle vector		
	containing the aac(3)IV gene and the	1	
	C31 attP site and integrase gene		
	pSET152 derivative for in trans		
nSI 2050	expressing tsrH with the 530 bp	Q	
pSL2050	upstream sequence and 288 bp		
	downstream region		

	pSL2050 derivative for in trans		
pSL3051	expressing the gene that encodes	4	
	TsrH- Ile1Val-Ala2Ser		
pWHU1001	pWHU2653 derivative containing sg	This study	
	sequence of <i>tsrT</i>		
WHH 1000	pWHU2653 derivative for tsrT in-	This study	
pwh01002	frame deletion		

Primer	Sequence
sg-for	accaccaccacCACTGAGCTAGCTTCAGACGTG
sg-rev	gactagaggatccccgggtaTCTAGAAAAAAAACCCCGCC
tsrT-sg-for	GCCACCACGAGAGCCGGGccgttttagagctagaaatagc
tsrT-sg-rev	GGCCCGGCTCTCGTGGTGGCgctggatcctaccaaccggc
tsrT-L-for	gcttgcggcagcgtg <u>aagctt</u> GCGATCTGCTGCGGGTACG
tsrT-L-rev	ccgtgtatccgggtggatctGGTTGGGG
tsrT-R-for	agatccacccggatacacggGCGCTTTCTG
tsrT-R-rev	gacctgcaggcatgc <u>aagctt</u> ACGGCGAACTGACCCTCTG
tsrT-Y-for	CGGGAGGCCCTGGCCTGGTACCGCTG
tsrT-Y-rev	TGACGTCGAGGAGCCGCCGGTTCCG

Table S2. Primers used in this study. Small letters indicate the vector sequences. Underscored letters indicate the recognition sites of restriction endonucleases.

Assignment	Н	С	НМВС	COSY
Val1-1		173 5	-	
Val1-2	3.01(d.3.96)	67.5	Val1-1 Val 1-3 Val 1-4	Val1-3
	0.01 (0, 0.) 0)	0,10	Val 1-5 0-7	
Val1-3	2.39 (m)	31.5	Val1-2 Val 1-4 Val 1-5	Val1-2 Val
vuli 5	2.37 (11)	51.5	vari 2, vari 1, vari 5	1_4_Val 1_5
V911-4	0.82(d.6.96)	167	Val1_2 Val 1_3 Val 1_5	Val1_3
Val1-4	1.11 (d. 6.9)	10.7	Val1-2, Val 1-3, Val 1-3 Val1-2, Val 1-3, Val $1-4$	Val1-3
$\frac{1}{2}$	1.11 (d, 0.9)	162.4	val1-2, val1-3, val1-4	v a11-5
Dha2-2		134.4		
Dha2-2	$H_{2} = 6 A A (d = 1 86)$	100.8	$Dh_{9}2_{-1}$ $Dh_{9}2_{-2}$	Dha2-3-Hh
Dhaz-5	Ha, 0.44 (0, 1.00)	100.8	Dha2-1, Dha2-2, $Dha2-1$	Dha2-3-110
Dho2 1	H0, 3.19 (8)	162.2	Dila2-1, Dila2-2	Dila2-3-fia
Dha2 2		105.5		
Dha $3-2$	$H_{0} = 5.91 (a)$	102.0	Dha2 1 $Dha2$ 2	Dha2 2 Lik
Dna5-5	Ha, 5.81 (s)	103.2	Dha $3-1$, Dha $3-2$	Dhas-s-Hb
	Hb, $5.42(8)$		Dha3-1, Dha3-2	Dna3-3-Ha
Dha3-NH	8.33 (bs)	150 5	Dha2-1,Dha3-1,Dha3-3	
Ala4-1		173.5		
Ala4-2	4.80 (q, 6.3)	52.1	Dha3-1, Ala4-1, Ala4-3	Ala4-3
Ala4-3	1.46 (d, 6.48)	19.1	Ala4-1, Ala4-2	Ala4-2
Ala4-NH	7.12 (d, 6.9)		Dha3-1, Ala4-1	
Pip5-1	5.36 (s)	64.6	Pip5-2, Pip5-4, Pip5-5,	
			Ala4-1, Ala4-2, Thz6-4,	
			Thz13-1, Thz13-2,	
Pip5-2		162.4		
Pip5-3	Ha, 2.98 (m)	26.1		Pip5-3-Hb,
				Pip5-4-Ha,
				Pip5-4-Hb
	Hb, 3.36 (m)			Pip5-3-Ha,
				Pip5-4-Ha
Pip5-4	Ha, 4.12 (m)	29.9	Pip5-1, Pip5-3, Pip5-5	Рір5-3-На,
				Pip5-3-Hb,
				Pip5-4-Hb
	Hb, 2.32 (m)		Pip5-1, Pip5-2, Pip5-3,	Pip5-3-Ha,
			Pip5-5, Thz13-1	Pip5-4-Ha
Pip5-5		57.9		
Pip5-NH	9.78 (s)		Ala4-1	
Thz6-1		161.0		
Thz6-2		146.6		
Thz6-3	8.20 (s)	126.2	Thz6-2, Thz6-4	
Thz6-4		170.2		
Thr7-1		166.8		

Table S3. ¹H and ¹³C NMR spectroscopic data for 5'-fluoro-SIO.

Thr7-2	4.46 (m)	55.9	Thr7-1, Thr7-3, Thr7-4,	Thr7-3
			Thz6-1	
Thr7-3	1.60 (m)	66.7		Thr7-2,
				Thr7-4
Thr7-4	0.85 (d, 6)	19.2	Thr7-2, Thr7-3	Thr7-3
Thr7-NH	7.19 (d, 6.9)		Thz6-1, Thr7-1	Thr7-2
Dhb8-1		128.8		
Dhb8-2	6.26 (q, 6.78)	132.1	Dhb8-1, Dhb8-3, Tzn9-1	Dhb8-3
Dhb8-3	1.64 (d, 7.02)	15.2	Dhb8-1, Dhb8-2, Tzn9-4	Dhb8-2
Dhb8-NH	8.74 (bs)		Dhb8-2	
Tzn9-1		170.6		
Tzn9-2	5.02 (dd,	79.3	Tzn9-1, Tzn9-3, Tzn9-4	Tzn9-3-Ha,
	9.78,11.94)			Tzn9-3-Hb
Tzn9-3	Ha,3.20 (m)	34.6	Tzn9-1, Tzn9-2	Tzn9-2,
				Tzn9-3-Hb
	Hb,3.66 (m)		Tzn9-1, Tzn9-4	Tzn9-2,
				Tzn9-Ha
Tzn9-4		170.6		
Ile10-1	5.78 (s)	53.3	Tzn9-1, Ile10-2, Thz11-4	
Ile10-2		76.7		
Ile10-3	3.84 (m)	67.5	Ile10-1, Ile10-2, Ile10-4,	Ile10-4
			Ile10-5	
Ile10-4	1.31 (d,6.3)	15.8	Ile10-2, Ile10-3	Ile10-3
Ile10-5	1.16 (s)	19.1	le10-1, le10-2, le10-3,	
			Tzn9-1	
Ile10-NH	7.60 (s)		Tzn9-1	Ile10-1
Thz11-1		166.9		
Thz11-2		146.6		
Thz11-3	8.19 (s)	125.5	Thz11-1, Thz11-2	
Thz11-4		165.9		
Thr12-1	5.81 (s)	55.9	Thz11-1, Thz13-3,	
			Thz12-2, Thz12-3	
Thr12-2	6.37 (m)	71.6	Thz12-3, Thz13-3, Q-1	Thz12-3
Thr12-3	1.67 (d, 6.48)	18.9	Thz12-1, Thz12-2	Thz12-2
Thz13-1		157.7		
Thz13-2	7.62 (s)	119.0	Thz13-1, Thz13-3, Pip5-1	
Thz13-3		170.1		
Thz14-1		160.1		
Thz14-2		150.3		
Thz14-3	8.31 (s)	128.2	Thz14-1, Thz14-2,	
			Thz14-4	
Thz14-4		166.0		
Dha15-1		162.4		
Dha15-2		134.4		

Dha15-3	Ha, 5.64 (s)	105.0	Dha15-1, Dha15-2	Dha15-3-Hb
	Hb, 6.73 (s)		Dha15-1, Dha15-2	Dha15-3-Ha
Dha16-1		166.6		
Dha16-2		134.6		
Dha16-3	Ha, 6.55 (bs)	103.8	Dha16-1, Dha16-2	Dha16-3-Hb
	Hb, 5.72 (bs)		Dha16-1, Dha16-2	Dha16-3-Ha
Q-1		160.8		
Q-2		145.1		
Q-3	7.57 (s)	123.7		
Q-4		155.9		
Q-5		170.1		
Q-6	6.0 (dd, 6.78,	107	Q-7, Q-8, Q-9, Q-10	Q-7
	6.84)			
Q-7	3.65 (m)	58.0	Q-5, Q-6, Q-8, Q-9, Val-2	Q-6, Q-8
Q-8	4.40 (s)	68.2	Q-6, Q-7, Q-9, Q-10	Q-7
Q-9		157.7		
Q-10		123.7		
Q-11	5.67 (q, 6.48)	65.8	Q-3, Q-4, Q-12	Q-12
Q-12	1.40 (d, 6.54)	22.9	Q-4, Q-11	Q-11

 Table S4. MALDI High Resolution MS DATA of 5'-fluoro-SIO.

Compound	5'-fluoro-SIO ^a
Found	1666.4574
Calculated	1666.4589
Formula	$C_{71}H_{81}N_{19}O_{18}S_5F$

a: [M+H]⁺

3. Supplementary references

- 1 T. Kieser et al., Practical Streptomyces Genetics (John Innes Foundation, 2000).
- 2 H. Zeng, S. Wen, W. Xu, Z. He, G. Zhai, Y. Liu, Z. Deng and Y. Sun, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 10575-10585.
- 3 R. Liao, L. Duan, C. Lei, H. Pan, Y. Ding, Q. Zhang, D. Chen, B. Shen, Y. Yu and W. Liu, *Chem. Biol.*, 2009, **16**, 141-147.
- 4 P. Duan, Q. Zheng, Z. Lin, S. Wang, D. Chen and W. Liu, Org. Chem. Front., 2016, 3, 1254-1258.
- 5 S. F. Wang, Q. F. Zheng, J. F. Wang, Z. X. Zhao, Q. Y. Li, Y. S. Yu, R. X. Wang and W. Liu, *Org. Chem. Front.*, 2015, **2**, 106-109.
- 6 N. Azizan, S. Mohd Said, Z. Zainal Abidin and I. Jantan, Molecules, 2017, 22.
- 7 K. Y. Lee, S. M. Cha, S. M. Choi and J. D. Cha, J. Oral. Sci., 2017, 59, 77-86.
- 8 H. Guo, J. Wang, Y. Li, Y. Yu, Q. Zheng, J. Wu and W. Liu, Chem. Sci., 2014, 5, 240-246.